Sugi Predict

Sugi Predict / Compounds / SCHEMBL4667674

SCHEMBL4667674

SCHEMBL4667674

Cc1cc2c(F)[c]ccc2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 2/20 0.43
▸ NFE2L2 Q16236 1/20 0.43
▸ NQO2 P16083 1/20 0.40
▸ GAA P10253 3/20 0.39
▸ RXFP1 Q9HBX9 2/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ ALDH1A1 P00352 6/20 0.38
▸ KDM4E B2RXH2 5/20 0.38
▸ MAPT P10636 3/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ HPGD P15428 5/20 0.36
▸ LMNA P02545 3/20 0.36
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2931891 0.80 NQO2 (0.42) KEAP1NFE2L2NQO2GAARXFP1
SCHEMBL32889381 0.72 KEAP1 (0.50) KEAP1NFE2L2NQO2GAARXFP1
SCHEMBL12475636 0.72 KEAP1 (0.50) KEAP1NFE2L2NQO2GAARXFP1
SCHEMBL4424885 0.71 NQO2 (0.57) KEAP1NFE2L2NQO2GAARXFP1
SCHEMBL30605955 0.68 DAO (0.53) KEAP1NFE2L2NQO2GAARXFP1
SCHEMBL370588 0.68 KEAP1 (0.50) KEAP1NFE2L2NQO2GAARXFP1
SCHEMBL4692767 0.68 DAO (0.53) KEAP1NFE2L2NQO2GAARXFP1
SCHEMBL1406090 0.68 KEAP1 (0.50) KEAP1NFE2L2NQO2GAARXFP1
SCHEMBL16892344 0.68 NQO2 (0.53) KEAP1NFE2L2NQO2GAARXFP1
SCHEMBL1392310 0.66 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118221577-A 2-Phenoxyquinoline derivative, and preparation method and application thereof 湖南中医药大学 2024-06-21 — — CN claimed
WO-2023165591-A1 COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS IMMUTHER PHARMATECH (SHANGHAI) CO., LTD. (CN) 2023-09-07 — — WO claimed
EP-1309587-B1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2008-12-31 — — EP claimed
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity HENNEQUIN LAURENT FRANCOIS ANDRE 2008-12-18 — — US claimed
US-7371765-B2 Quinoline derivatives having VEGF inhibiting activity ASTRAZENECA AB (SE) 2008-05-13 — — US claimed
US-20060148819-A1 Chemical compounds HENNEQUIN LAURENT F A 2006-07-06 — — US claimed
US-6887874-B2 Cinnoline compounds ASTRAZENECA AB (SE) 2005-05-03 — — US claimed
US-20030212055-A1 Cinnoline compounds ASTRAZENECA AB (SE) 2003-11-13 — — US claimed
US-20030207878-A1 Chemical compounds ASTRAZENECA AB (SE) 2003-11-06 — — US claimed
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity ASTRAZENECA AB (SE) 2003-10-23 — — US claimed
EP-1313726-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY AstraZeneca AB (SE) 2003-05-28 — — EP claimed
EP-1311500-A2 INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY AstraZeneca AB (SE) 2003-05-21 — — EP claimed
EP-1309587-A1 CINNOLINE COMPOUNDS AstraZeneca AB (SE) 2003-05-14 — — EP claimed
WO-2002016348-A1 ANTIANGIOGENIC BICYCLIC DERIVATIVES ASTRAZENECA AB (SE) 2002-02-28 — — WO claimed
WO-2002012226-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 — — WO claimed
WO-2002012228-A1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2002-02-14 — — WO claimed
WO-2002012227-A2 INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 — — WO claimed
CN-118221577-A 2-Phenoxyquinoline derivative, and preparation method and application thereof 湖南中医药大学 2024-06-21 — — CN disclosed
WO-2002012227-A2 INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 — — WO disclosed
WO-2002012226-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity VEGFA, FLT1, FLT4 KEAP1 2605/4885NFE2L2 1665/4885NQO2 55/4885
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity VEGFA, FLT1, FLT4 KEAP1 2578/4885NFE2L2 1370/4885NQO2 193/4885
US-20060148819-A1 Chemical compounds VEGFA, NOS3, FLT4 KEAP1 2377/4885NFE2L2 1899/4885NQO2 43/4885
US-20030207878-A1 Chemical compounds CYP3A7, HTR3C, CNR1 KEAP1 1258/4885NFE2L2 2385/4885NQO2 28/4885
US-20030212055-A1 Cinnoline compounds VEGFA, PGF, CCR7 KEAP1 2952/4885NFE2L2 3615/4885NQO2 1129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.